A phase I pharmacokinetic (PK) study of MBP-426, a novel liposome encapsulated oxaliplatin
Kamalesh K. Sankhala(The University of Texas at San Antonio Health Science Center), Alexandria T. Phan(Methodist Hospital), N. Yamagata(The University of Texas at San Antonio Health Science Center), Akira Mita(Mary Crowley Cancer Research Center), STEPHEN BULLOCK(The University of Texas at San Antonio Health Science Center), Kumi Matsuno(The University of Texas at San Antonio Health Science Center), Laurence M. Wood(Texas Tech University), Toshimitsu FUJISAWA(The University of Texas at San Antonio Health Science Center), R. Adinin(The University of Texas at San Antonio Health Science Center), Muralidhar Beeram(Urology San Antonio)
Cited by 82
Related Papers
Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
|Clinical Cancer Research|2015|799
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers
|Journal of Clinical Oncology|2019|590
The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer
|Clinical Cancer Research|2012|432